S&P 500   3,295.25 (+0.74%)
DOW   26,558.59 (+0.15%)
QQQ   275.21 (+1.31%)
AAPL   114.68 (+3.13%)
MSFT   204.53 (+0.91%)
FB   281.24 (+5.07%)
GOOGL   1,551.23 (+2.68%)
AMZN   3,188.38 (+0.81%)
TSLA   413.32 (+1.80%)
NVDA   519.90 (+2.93%)
BABA   309.63 (+0.55%)
CGC   18.32 (-0.11%)
GE   7.36 (-0.81%)
MU   50.19 (+0.38%)
AMD   77.89 (+1.95%)
T   26.81 (+1.17%)
F   7.96 (+3.38%)
ACB   3.84 (+0.26%)
GILD   57.46 (-2.15%)
NFLX   481.70 (-0.93%)
NIO   30.09 (+9.38%)
BA   146.99 (-0.78%)
DIS   119.78 (+1.11%)
S&P 500   3,295.25 (+0.74%)
DOW   26,558.59 (+0.15%)
QQQ   275.21 (+1.31%)
AAPL   114.68 (+3.13%)
MSFT   204.53 (+0.91%)
FB   281.24 (+5.07%)
GOOGL   1,551.23 (+2.68%)
AMZN   3,188.38 (+0.81%)
TSLA   413.32 (+1.80%)
NVDA   519.90 (+2.93%)
BABA   309.63 (+0.55%)
CGC   18.32 (-0.11%)
GE   7.36 (-0.81%)
MU   50.19 (+0.38%)
AMD   77.89 (+1.95%)
T   26.81 (+1.17%)
F   7.96 (+3.38%)
ACB   3.84 (+0.26%)
GILD   57.46 (-2.15%)
NFLX   481.70 (-0.93%)
NIO   30.09 (+9.38%)
BA   146.99 (-0.78%)
DIS   119.78 (+1.11%)
S&P 500   3,295.25 (+0.74%)
DOW   26,558.59 (+0.15%)
QQQ   275.21 (+1.31%)
AAPL   114.68 (+3.13%)
MSFT   204.53 (+0.91%)
FB   281.24 (+5.07%)
GOOGL   1,551.23 (+2.68%)
AMZN   3,188.38 (+0.81%)
TSLA   413.32 (+1.80%)
NVDA   519.90 (+2.93%)
BABA   309.63 (+0.55%)
CGC   18.32 (-0.11%)
GE   7.36 (-0.81%)
MU   50.19 (+0.38%)
AMD   77.89 (+1.95%)
T   26.81 (+1.17%)
F   7.96 (+3.38%)
ACB   3.84 (+0.26%)
GILD   57.46 (-2.15%)
NFLX   481.70 (-0.93%)
NIO   30.09 (+9.38%)
BA   146.99 (-0.78%)
DIS   119.78 (+1.11%)
S&P 500   3,295.25 (+0.74%)
DOW   26,558.59 (+0.15%)
QQQ   275.21 (+1.31%)
AAPL   114.68 (+3.13%)
MSFT   204.53 (+0.91%)
FB   281.24 (+5.07%)
GOOGL   1,551.23 (+2.68%)
AMZN   3,188.38 (+0.81%)
TSLA   413.32 (+1.80%)
NVDA   519.90 (+2.93%)
BABA   309.63 (+0.55%)
CGC   18.32 (-0.11%)
GE   7.36 (-0.81%)
MU   50.19 (+0.38%)
AMD   77.89 (+1.95%)
T   26.81 (+1.17%)
F   7.96 (+3.38%)
ACB   3.84 (+0.26%)
GILD   57.46 (-2.15%)
NFLX   481.70 (-0.93%)
NIO   30.09 (+9.38%)
BA   146.99 (-0.78%)
DIS   119.78 (+1.11%)
Log in
FRA:MRK

Merck KGaA Competitors

€134.75
-0.45 (-0.33 %)
(As of 10/28/2020 12:00 AM ET)
Add
Compare
Today's Range
€133.00
Now: €134.75
€136.95
50-Day Range
€117.80
MA: €126.04
€135.20
52-Week Range
€76.60
Now: €134.75
€115.00
Volume903,504 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Merck KGaA (FRA:MRK) Vs. AGN, AMS, BAYN, DIA, EI, and FRE

Should you be buying MRK stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Merck KGaA, including AEGON (AGN), American Shared Hospital Services (AMS), Bayer (BAYN), DiaSorin (DIA), Essilor International Société Anonyme (EI.PA) (EI), and Fresenius SE & Co. KGaA (FRE.F) (FRE).

AEGON (AMS:AGN) and Merck KGaA (FRA:MRK) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Earnings and Valuation

This table compares AEGON and Merck KGaA's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AEGONN/AN/AN/AN/AN/A
Merck KGaAN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings for AEGON and Merck KGaA, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AEGON0000N/A
Merck KGaA19402.21

Merck KGaA has a consensus target price of €121.31, indicating a potential downside of 9.98%.

Profitability

This table compares AEGON and Merck KGaA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AEGONN/AN/AN/A
Merck KGaAN/AN/AN/A

Summary

Merck KGaA beats AEGON on 1 of the 1 factors compared between the two stocks.

American Shared Hospital Services (BME:AMS) and Merck KGaA (FRA:MRK) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Profitability

This table compares American Shared Hospital Services and Merck KGaA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
American Shared Hospital ServicesN/AN/AN/A
Merck KGaAN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations for American Shared Hospital Services and Merck KGaA, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
American Shared Hospital Services0000N/A
Merck KGaA19402.21

Merck KGaA has a consensus target price of €121.31, indicating a potential downside of 9.98%.

Valuation & Earnings

This table compares American Shared Hospital Services and Merck KGaA's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
American Shared Hospital ServicesN/AN/AN/AN/AN/A
Merck KGaAN/AN/AN/AN/AN/A

Summary

Merck KGaA beats American Shared Hospital Services on 1 of the 1 factors compared between the two stocks.

Bayer (FRA:BAYN) and Merck KGaA (FRA:MRK) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership and profitability.

Valuation & Earnings

This table compares Bayer and Merck KGaA's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BayerN/AN/AN/AN/AN/A
Merck KGaAN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for Bayer and Merck KGaA, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bayer051202.71
Merck KGaA19402.21

Bayer presently has a consensus target price of €73.38, indicating a potential upside of 80.26%. Merck KGaA has a consensus target price of €121.31, indicating a potential downside of 9.98%. Given Bayer's stronger consensus rating and higher probable upside, analysts clearly believe Bayer is more favorable than Merck KGaA.

Profitability

This table compares Bayer and Merck KGaA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BayerN/AN/AN/A
Merck KGaAN/AN/AN/A

Summary

Bayer beats Merck KGaA on 3 of the 3 factors compared between the two stocks.

DiaSorin (BIT:DIA) and Merck KGaA (FRA:MRK) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.

Profitability

This table compares DiaSorin and Merck KGaA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DiaSorinN/AN/AN/A
Merck KGaAN/AN/AN/A

Valuation & Earnings

This table compares DiaSorin and Merck KGaA's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DiaSorinN/AN/AN/AN/AN/A
Merck KGaAN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings for DiaSorin and Merck KGaA, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DiaSorin0000N/A
Merck KGaA19402.21

Merck KGaA has a consensus target price of €121.31, indicating a potential downside of 9.98%.

Summary

Merck KGaA beats DiaSorin on 1 of the 1 factors compared between the two stocks.

Merck KGaA (FRA:MRK) and Essilor International Société Anonyme (EI.PA) (EPA:EI) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Valuation & Earnings

This table compares Merck KGaA and Essilor International Société Anonyme (EI.PA)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck KGaAN/AN/AN/AN/AN/A
Essilor International Société Anonyme (EI.PA)N/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Merck KGaA and Essilor International Société Anonyme (EI.PA), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merck KGaA19402.21
Essilor International Société Anonyme (EI.PA)0000N/A

Merck KGaA presently has a consensus price target of €121.31, suggesting a potential downside of 9.98%. Given Merck KGaA's higher possible upside, equities research analysts clearly believe Merck KGaA is more favorable than Essilor International Société Anonyme (EI.PA).

Profitability

This table compares Merck KGaA and Essilor International Société Anonyme (EI.PA)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merck KGaAN/AN/AN/A
Essilor International Société Anonyme (EI.PA)N/AN/AN/A

Summary

Merck KGaA beats Essilor International Société Anonyme (EI.PA) on 2 of the 2 factors compared between the two stocks.

Fresenius SE & Co. KGaA (FRE.F) (FRA:FRE) and Merck KGaA (FRA:MRK) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for Fresenius SE & Co. KGaA (FRE.F) and Merck KGaA, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fresenius SE & Co. KGaA (FRE.F)141102.63
Merck KGaA19402.21

Fresenius SE & Co. KGaA (FRE.F) presently has a consensus target price of €51.46, suggesting a potential upside of 58.97%. Merck KGaA has a consensus target price of €121.31, suggesting a potential downside of 9.98%. Given Fresenius SE & Co. KGaA (FRE.F)'s stronger consensus rating and higher possible upside, research analysts clearly believe Fresenius SE & Co. KGaA (FRE.F) is more favorable than Merck KGaA.

Valuation and Earnings

This table compares Fresenius SE & Co. KGaA (FRE.F) and Merck KGaA's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fresenius SE & Co. KGaA (FRE.F)N/AN/AN/AN/AN/A
Merck KGaAN/AN/AN/AN/AN/A

Profitability

This table compares Fresenius SE & Co. KGaA (FRE.F) and Merck KGaA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fresenius SE & Co. KGaA (FRE.F)N/AN/AN/A
Merck KGaAN/AN/AN/A

Summary

Fresenius SE & Co. KGaA (FRE.F) beats Merck KGaA on 3 of the 3 factors compared between the two stocks.


Merck KGaA Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AEGON logo
AGN
AEGON
0.5N/AN/A$0.00N/A0.00
AMS
American Shared Hospital Services
0.5N/AN/A$0.00N/A0.00
Bayer logo
BAYN
Bayer
1.5$40.71-2.9%$0.00N/A0.00Analyst Report
DIA
DiaSorin
0.6N/AN/A$0.00N/A0.00
Essilor International Société Anonyme (EI.PA) logo
EI
Essilor International Société Anonyme (EI.PA)
0.5$126.85-0.0%$0.00N/A0.00
Fresenius SE & Co. KGaA (FRE.F) logo
FRE
Fresenius SE & Co. KGaA (FRE.F)
1.5$32.37-3.2%$0.00N/A0.00Analyst Report
Heavy News Reporting
GNFT
Genfit SA (GNFT.PA)
0.5$3.19-1.6%$0.00N/A0.00High Trading Volume
Heavy News Reporting
Novartis logo
NOVN
Novartis
1.3N/AN/A$0.00N/A0.00Analyst Report
Sanofi (SAN.PA) logo
SAN
Sanofi (SAN.PA)
1.4$79.04-2.5%$0.00N/A0.00
Sartorius logo
SRT3
Sartorius
0.8$381.00-0.5%$0.00N/A0.00Analyst Report
Sartorius Stedim Biotech S.A. (DIM.PA) logo
DIM
Sartorius Stedim Biotech S.A. (DIM.PA)
0.5$325.40-0.7%$0.00N/A0.00Heavy News Reporting
STADA Arzneimittel Aktiengesellschaft (SAZ.F) logo
SAZ
STADA Arzneimittel Aktiengesellschaft (SAZ.F)
0.4$80.40-0.0%$0.00N/A0.00
TEV
Teva Pharmaceutical Industries Limited (TEV.F)
0.5N/AN/A$0.00N/A0.00High Trading Volume
This page was last updated on 10/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.